Adial Pharmaceuticals, Inc.: Executive or director change
Adial Pharmaceuticals held its 2026 annual meeting, approving an increase in authorized shares and equity plans while adjourning four proposals pending Nasdaq review.
Neutral newsWhat happened
- Stockholders approved increasing authorized common stock from 100,000,000 to 500,000,000 shares.
The full interpretation is in the app
Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.
Read the full interpretation